Trials & Tribulations Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients March 27, 2026Vol.52 No.12By W. Kimryn Rathmell
In Brief Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition March 06, 2026Vol.52 No.09
In Brief Katie Coleman named senior advisor for translational innovation at OSUCC–James January 16, 2026Vol.52 No.02
In Brief Alex Bates named director for executive communications at the OSUCCC–James January 16, 2026Vol.52 No.02
In Brief Ohio State to be awarded funding to optimize sarcoma treatment December 19, 2025Vol.51 No.46
Clinical Roundup Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds December 19, 2025Vol.51 No.46
Podcast In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research” June 04, 2025Vol.51 No.21
Conversation with The Cancer Letter We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James May 30, 2025Vol.51 No.21By Paul Goldberg
Guest Editorial In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same April 25, 2025Vol.51 No.16By W. Kimryn Rathmell
In Brief W. Kimryn Rathmell named CEO of The Ohio State James Cancer Hospital and Solove Research Institute April 25, 2025Vol.51 No.16
